CONSENSUS OUTLOOK: MULTIPLE SCLEROSIS

Consensus Outlook: Multiple Sclerosis

Latest Update:
December 2013
Format:
PDF + Excel
Pages:
33 + Data File

Price:

$4,995 Single User License

Single user licenseAuthorizes use by the person placing the order only.


$9,990 Team License

Team licenseAuthorizes use by up to 10 employees of the Licensee who work within the same team or functional business unit.


$14,985 Global License

Global licenseAuthorizes use by any employee of the Licensee, including employees of the Licensee's affiliates.



ORDER NOW!

Related research module:
KOL Insight: Multiple Sclerosis

Order both modules and save 25%

Pages:
183 + Data File

Price for both modules:

$7,495 Single User License

Single user licenseAuthorizes use by the person placing the order only.


$14,990 Team License

Team licenseAuthorizes use by up to 10 employees of the Licensee who work within the same team or functional business unit.


$22,485 Global License

Global licenseAuthorizes use by any employee of the Licensee, including employees of the Licensee's affiliates.



ORDER BOTH MODULES

Charting the Future Multiple Sclerosis Market Landscape

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.3 billion in 2012 to $21.5 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

  • An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
  • A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
  • Timely event-driven market forecast report and data analysis updates over the next 12 months

Contact us to learn more

Understand the Unique Benefits of Consensus Outlook

  • Evaluate future sales forecasts and predicted market growth
  • Map your market parameters and chart commercial prospects
  • Assess market share by company and product
  • Tailor your strategic and investment focus based on the competition
  • Set proactive launch and branding strategies
  • Keep up with event-driven market data updates

Contact us to learn more

Content Highlights

  1. Forecast Data Model (Excel)
    Tabs:
    • Market size
    • Product sales
    • Company forecast
    • Mechanism of action
    • Future Events
  2. Forecast Analysis Report (PDF)
    Contents:
    • FirstWord Analysis Highlights
    • Research Methodology
    • Multiple Sclerosis Marketplace
    • Key Multiple Sclerosis Developers
    • Multiple Sclerosis Class Dynamics
    • Tecfidera (dimethyl fumarate; Biogen) forecast
    • Aubagio (teriflunomide; Sanofi) forecast
    • Gilenya (fingolimod; Novartis Mitsubishi Tanabe) forecast
    • Tysabri (natalizumab; Biogen) forecast
    • Copaxone (glatiramer acetate; Teva) forecast
    • Avonex (interferon beta-1a; Biogen) forecast
    • Betaseron (interferon beta-1b; Bayer) forecast
    • Rebif (interferon beta-1a; Merck Serono) forecast
    • Extavia (interferon beta-1b; Novartis) forecast
    • Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast
    • Laquinimod (Teva/Active Biotech) forecast
    • Daclizumab HYP (Biogen/AbbVie) forecast
    • Ocrelizumab (Biogen/Roche/Biogen) forecast

Contact us to learn more

Mapping Future Events to Product Sales Forecasts

The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Report features:
  • Historical MS sales from 2007–2012
  • Forecast MS sales from 2013-2017
  • Key competitors and drug developers
  • Predicted product positioning
  • Current and late-stage pipeline drugs
  • Future event mapping to forecast data points
  • Comparative clinical trial results

Contact us to learn more

Interactive Product and Market Forecast Data Model

FirstWord’s MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.

  • Market size
  • Product sales
  • Company forecasts
  • Company, brand,
    and drug class
  • Mechanism of action
  • Future events

Contact us to learn more

Forecasts and Analysis Updated Within Days of Major Market Events

Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.

Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.

Example table below taken from TT RA CO report

Contact us to learn more

An approach backed by unrivalled knowledge and market intimacy

For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.

Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.

Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.

Contact us to learn more